Closed – 2024

Nano and advanced technologies for disease prevention, diagnostic and therapy (NANOTECMEC) – ERA4Health 2024

The French National Research Agency, in partnership with fifteen countries (Austria, Belgium- including Wallonia-Brussels, Flanders-, Estonia, Israel, Italy, Latvia, Lithuania, Norway, Poland, Portugal, Romania, Slovakia, Spain -including region of Andalusia-, Taiwan, the Netherlands) is launching the novel international call for projects on health and wellbeing under the umbrella of the Partnership ERA4Health (“Fostering a European Research Area for Health”).The total budget for this action is about of 18.5 million euros.

The aim of this call is to enable scientists in different countries to build a valuable collaboration on common interdisciplinary research projects based on complementarities and sharing of expertise in the field of nanomedicine with a clear translational research approach. More precisely, proposals must present research that covers at least one of the following topics:

a) Regenerative medicine
b) Diagnostics
c) Nanotherapy

Nanomedicine has the potential to enable early detection and prevention of diseases, and to significantly improve diagnosis, treatment and follow-up of diseases. In addition, the integration of Key Enabling Technologies (KET) to nanotechnologies will offer even greater possibilities of nanomedicine to foster innovation for new medical applications. Studies of other KET is possible only if they are used in complement or in combination with nanotechnologies.

Only transnational projects will be funded. The following conditions apply to the composition of consortia:

  • Minimum of three eligible and a maximum of five eligible partners from at least three different countries participating in the call.
  • No more than two eligible partners from the same country participating in the call will be accepted within one consortium.
  • The maximum number of eligible partners can be increased up to six or seven (see table below) if they include one or two partners, respectively, from the following participating countries: Latvia, Lithuania, Slovakia, Türkiye.
  • Maximum of two collaborators per consortium. Collaborators are self-funded partners: i.e. partners that are not requesting funds in this Joint Transnational Call provided by one of the participating funding organisations (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding organisations).

ANR will only fund the French partners of the selected projects. In agreement with ANR policy, funded researchers should respect the guidelines of the Nagoya protocol and consider open access publication of their results.

Call text modifications:
27/11/2023 - Inclusion of TUBITAK (Turkey) and as participating funding organisations.
29/11/2023 - Modification of the « Eligibility of Partners » section in RCN National Annex
           - Modification of ANR National Annex : link in « Further guidance » section
30/11/2023 - Modification of the « Eligibility of Partners » section in RCN National Annex

Opening : 2023-11-28 at 09:00 CET
Pre-proposal deadline : 2024-01-30 at 16:00 CET
Application Deadline : 2024-06-13 at 16:00 CEST

The call will follow a two-step evaluation procedure.

Call text and proposal template can be found on ERA4Health website.

Proposals should be submitted online using the submission website (ANR will not accept any proposal submission and no additional information is required by ANR at the submission stage).

NANOTECMEC Call secretariat:

Anaïs Fradet / Mérick Machouri
+33 1 73 54 81 74 /+33 1 72 73 06 72


Consult the upcoming and current calls of the portal

The portal centralises all information on calls for proposals and calls for applications from ADEME, ANR, Inserm including ANRS, Anses and INCa. It provides a simplified access to upcoming and ongoing calls, giving a greater visibility to funding opportunities. Following their closing date, the calls remain published for a few months.


Sign up for the latest news:
Subscribe to our newsletter